cell
ie
cell
monocyt
macrophag
dendrit
cell
declin
tcell
advanc
stage
infect
respons
profound
immun
suppress
character
advanc
stage
aid
howev
advent
highli
activ
antiretrovir
therapi
haart
combin
drug
inhibit
replic
led
reduc
viremia
onset
opportunist
infect
patient
prolong
surviv
chemotherapi
main
mode
treatment
aid
common
class
drug
employ
treatment
hiv
infect
design
inhibit
particular
stage
infecti
cycl
hiv
fig
depict
differ
target
variou
antiretrovir
drug
entri
inhibitor
compris
fusion
inhibitor
coreceptor
inhibitor
prevent
entri
hiv
host
cell
fusion
inhibitor
interact
viral
envelop
therebi
block
fusion
cell
membran
coreceptor
inhibitor
interact
receptor
host
cell
prevent
interact
viru
proteas
inhibitor
pi
interfer
proteolyt
process
viral
protein
bind
interact
activ
site
hiv
proteas
revers
transcriptas
inhibitor
form
major
class
antiretrovir
drug
molecul
disrupt
transform
singl
strand
rna
viral
genom
doubl
strand
dna
refer
nucleosid
revers
transcriptas
inhibitor
nrti
nucleotid
revers
transcriptas
inhibitor
ntrti
respect
inhibitor
bind
directli
revers
transcriptas
enzym
thu
block
hiv
life
cycl
relat
class
drug
known
nonnucleosid
revers
transcriptas
inhibitor
nnrti
bind
alloster
site
revers
transcriptas
result
inhibit
enzym
activ
recent
addit
repertoir
antiretrovir
drug
integras
inhibitor
interfer
integr
viral
genom
host
cell
list
antihiv
drug
list
tabl
antiretrovir
therapi
arv
significantli
reduc
aidsrel
morbid
mortal
howev
sever
drawback
current
arv
therapi
drug
resist
one
major
problem
antihiv
drug
therapi
resist
process
hiv
replic
rapid
errorpron
billion
viral
particl
produc
daili
basi
gener
least
one
mutat
per
genom
genet
mutat
enabl
viru
develop
resist
antihiv
drug
therapi
especi
monotherapi
employ
exampl
emerg
select
hiv
subtyp
c
viru
india
contain
multipl
nfkb
site
strengthen
promot
viru
b
longterm
drug
therapi
natur
hiv
infect
includ
viral
persist
reservoir
necessit
longterm
uninterrupt
multidrug
arv
therapi
treatment
complianc
critic
regardless
whether
patient
treatmentexperienc
sinc
poor
patient
complianc
often
factor
treatment
failur
viral
rebound
lack
patient
adher
complic
drug
administr
regimen
exacerb
cumul
cost
combin
arv
therapi
c
toxic
drugdrug
interact
prolong
treatment
arv
drug
result
sever
sideeffect
includ
constip
fever
liver
disord
muscular
dystrophi
metabol
disord
peripher
neuropathi
use
combin
drug
convent
therapi
also
lead
undesir
drugdrug
interact
therebi
reduc
efficaci
drug
instanc
combin
revers
transcriptas
inhibitor
nevirapin
proteas
inhibitor
saquinavir
use
treat
hiv
infect
saquinavir
level
plasma
found
drop
rapidli
due
induct
liver
cytochrom
nevirapin
lead
metabol
saquinavir
subsequ
elimin
therefor
reduc
avail
efficaci
poor
bioavail
arv
drug
burden
poor
pharmacokinet
arv
drug
formul
solid
dosag
form
oral
rout
administr
oral
dosag
form
offer
conveni
combin
dose
compound
make
therapeut
regimen
usual
high
high
dose
prefer
treatment
object
complet
inhibit
viral
prolifer
effect
proport
drug
concentr
deliveri
drug
via
oral
rout
suffer
signific
firstpass
effect
variat
absorpt
degrad
gastrointestin
tract
due
enzym
extrem
ph
condit
lead
low
errat
bioavail
exampl
express
multidrug
resist
efflux
protein
mrp
pglycoprotein
pgp
gastrointestin
tract
decreas
oral
bioavail
metabolismelimin
transport
barrier
substanti
reduc
effect
amount
antihiv
drug
reach
target
action
site
halflif
sever
arv
drug
short
requir
frequent
administr
dose
lead
poor
patient
complianc
short
resid
time
reduc
halflif
drug
plasma
necessit
frequent
administr
booster
dosag
well
increas
drug
dosag
contribut
develop
drug
resist
antiretrovir
drug
saquinavir
possess
poor
bioavail
due
metabol
liver
enzym
e
lack
access
tissu
reservoir
antiretrovir
drug
cross
bloodbrain
barrier
bbb
result
ineffect
enter
microgli
cell
astrocyt
hoard
hiv
particl
major
factor
high
protein
bind
antihiv
drug
prevent
diffus
across
bbb
also
observ
antiretrovir
drug
unabl
reach
lymphat
system
harbor
hiv
thu
convent
therapi
ineffect
annihil
viral
reservoir
less
lymphat
cell
present
system
circul
cell
lymphat
system
like
macrophag
dendrit
cell
involv
transmiss
viru
h
cell
helper
lymphocyt
failur
target
reservoir
hiv
increas
risk
viral
relaps
posttreat
emerg
newer
approach
counter
problem
convent
arv
therapi
circumv
problem
mention
effect
treat
hiv
infect
recent
antiaid
therapeut
develop
effort
focus
improv
drug
deliveri
discov
new
chemic
entiti
effort
made
design
novel
drug
deliveri
system
antihiv
agent
reduc
dose
frequenc
enhanc
bioavail
improv
central
nervou
system
cn
penetr
inhibit
cn
efflux
deliv
target
cell
select
minim
side
effect
among
recent
approach
novel
drug
deliveri
system
antihiv
drug
targetedintracellular
drug
deliveri
host
cell
capabl
get
infect
hiv
specif
hivinfect
cell
reservoir
hold
great
promis
main
aim
drug
target
optim
drug
therapeut
index
strictli
local
pharmacolog
activ
site
organ
action
result
target
would
signific
reduct
drug
toxic
reduct
drug
dose
increas
treatment
efficaci
hiv
infect
viru
infect
specif
cell
immun
system
includ
tcell
macrophag
dendrit
cell
form
strong
rational
target
deliveri
antihiv
drug
specif
cell
increas
efficaci
therapi
drug
deliveri
hivinfect
tissu
cell
select
achiev
target
surfac
marker
tcell
macrophag
dendrit
cell
toward
cn
target
receptor
two
effect
prophylact
protect
cell
occupi
receptor
necessari
viruscel
interact
andor
ii
improv
specif
uptak
nanocarri
load
antivir
drug
regard
sever
molecul
viral
host
cell
origin
describ
recent
year
would
enabl
target
drug
deliveri
hiv
infect
follow
review
provid
brief
overview
recent
develop
identif
novel
viral
hostcel
molecul
target
drug
deliveri
antihiv
drug
schemat
represent
differ
type
viral
host
target
investig
specif
target
hivinfect
cell
thu
far
shown
fig
conserv
region
hiv
envelop
glycoprotein
involv
bind
viru
host
cell
mani
target
strategi
focus
bind
protein
sequenc
achiev
specif
though
high
rate
mutat
exhibit
retroviru
make
challeng
identifi
suitabl
target
sequenc
envelop
present
outer
envelop
hiv
enabl
entri
viru
particl
tcell
mainli
bind
receptor
tlymphocyt
h
cell
macrophag
aid
viral
entri
help
fusion
protein
upon
infect
mainli
expos
surfac
hiv
infect
cell
henc
attract
target
cellspecif
deliveri
antiretrovir
drug
immunoliposom
carrier
encapsul
proteas
inhibitor
surfac
modifi
report
exhibit
excel
specif
toward
hiv
infect
cell
due
bind
expos
domain
present
surfac
hiv
infect
cell
actinohivin
prokaryot
lectin
found
actinomycet
identifi
possess
antihiv
activ
found
specif
target
hiv
infect
cell
lectin
belong
famili
carbohydr
bind
agent
cba
display
high
affin
bind
mannos
residu
chain
high
mannosetyp
glycan
associ
hiv
earlier
work
glycosylphosphatidylinositol
gpi
moieti
conjug
incorpor
liposom
found
select
bind
cell
comparison
liposom
liposom
vesicl
form
compon
viral
envelop
reveal
differ
intracellular
local
two
system
carrier
intern
mediat
endocytosi
infer
differ
lipid
composit
two
system
influenc
intracellular
compartment
facet
howev
remain
larg
unexplor
context
target
nanocarri
deliveri
antiretrovir
mesopor
silica
nanoparticl
highli
orient
access
pore
function
fragment
design
either
amid
conjug
glycosyl
linkag
function
nanoparticl
exhibit
excel
bind
protein
recent
loop
identifi
region
involv
initi
entri
viru
cell
antibodi
loop
found
inhibit
entri
virion
antibodi
loop
also
use
target
hiv
infect
cell
therebi
confer
target
specif
antivir
activ
anoth
strategi
involv
use
trifunct
igglik
bispecif
antibodi
domain
report
trifunct
antibodi
contain
two
bind
site
differ
molecul
report
display
nearli
enhanc
target
specif
compar
convent
antibodi
seek
singl
target
bispecif
antibodi
report
hiv
infect
cell
found
bind
specif
fragment
expos
infect
cell
well
compon
complement
result
activ
complementmedi
lysi
infect
cell
broad
activ
antibodi
also
use
target
hiv
infect
cell
display
higher
affin
even
nanomolar
concentr
crystal
structur
analysi
bind
fragment
reveal
hloop
contain
uniqu
sequenc
serin
tyrosin
residu
phenyl
alanin
residu
apex
propos
phenyl
alanin
residu
associ
bind
pocket
similar
phenyl
alanin
residu
host
cell
serin
tyrosin
residu
hloop
stabil
bind
format
hydrogen
bond
novel
approach
mimet
peptid
coval
link
heparan
sulfat
synthes
inhibit
entri
host
cell
mimet
peptid
specif
bind
result
conform
chang
expos
glycoproteinbind
domain
interact
heparan
sulfat
moieti
therebi
block
interact
viral
host
cell
receptor
recombin
peptid
express
bind
region
design
pseudomona
toxin
develop
specif
target
destroy
hiv
infect
cell
peptid
found
specif
bind
expos
region
found
surfac
hiv
infect
cell
surfact
protein
extract
lung
surfact
spd
belong
lectin
famili
found
display
high
affin
calciumdepend
bind
glycosyl
residu
use
solubl
immunoadhesin
molecul
target
hiv
infect
cell
also
report
molecul
found
bind
hiv
infect
cell
domain
expos
surfac
infect
cell
conjug
larg
antibodi
surfac
nanoparticl
tediou
risk
denatur
loss
proper
orient
conduc
ligand
bind
high
smaller
molecul
display
similar
specif
affin
target
antigen
explor
aptam
class
small
molecul
either
oligonucleotid
peptid
exhibit
high
bind
affin
target
molecul
suitabl
altern
antibodi
substitut
rna
bind
aptam
specif
bind
surfac
glycoprotein
report
display
excel
target
specif
studi
use
aptam
conjug
nanoparticl
system
warrant
improv
therapi
fig
depict
schemat
represent
concept
target
hiv
infect
cell
transmembran
protein
present
hiv
envelop
facilit
fusion
viru
cell
moieti
attach
noncoval
larger
involv
bind
viral
particl
cell
bind
receptor
host
cell
caus
conform
chang
lead
releas
stabl
ectodomain
aid
fusion
viru
host
cell
protein
contain
variou
subunit
fusion
peptid
ntermin
heptad
repeat
ctermin
heptad
repeat
membran
proxim
extracellular
region
similar
also
express
surfac
hiv
infect
cell
henc
attract
target
therapeut
strategi
involv
select
deliveri
therapeut
agent
hiv
infect
cell
antibodi
employ
target
hiv
infect
cell
case
radio
immunotherapi
rit
use
antibodi
label
rhenium
employ
target
hiv
infect
cell
contain
viral
particl
bud
cell
radioact
element
caus
death
hiv
infect
cell
strategi
success
demonstr
vivo
reduct
viral
load
report
recent
new
strategi
report
target
use
two
antigen
determin
singl
antibodi
known
doubl
variabl
domain
immunoglobulin
dvd
use
dvd
promot
greater
interact
two
glycoprotein
domain
hiv
infect
cell
result
higher
uptak
immunoconjug
therebi
lead
superior
viral
load
reduct
similar
strategi
lu
et
al
report
recombin
bival
protein
contain
fragment
peptid
domain
bind
interact
nhr
trimer
repeat
result
decay
thu
prevent
fusion
hiv
virion
uninfect
cell
recombin
protein
may
also
use
conjug
nanoparticl
target
hiv
infect
cell
though
approach
explor
thu
far
mani
engin
peptid
develop
target
instanc
identifi
peptid
bind
specif
ntermin
heptad
region
inhibit
infect
virion
due
prevent
conform
chang
respons
viral
entri
sequenc
deriv
similar
peptid
also
deriv
design
bind
inactiv
interact
cheptad
repeat
chr
domain
lead
inactiv
env
gene
engin
peptid
interact
specif
expos
region
hiv
prevent
entri
viru
cell
membran
proxim
extern
region
mper
also
highli
conserv
region
contain
amino
acid
antibodi
domain
prove
success
target
hiv
infect
cell
surprisingli
though
sever
molecul
target
conserv
region
viru
identifi
integr
target
molecul
antiretrovir
drug
contain
nanoparticl
extens
investig
remain
infanc
yet
anoth
interest
approach
target
hivinfect
cell
identifi
uniqu
marker
host
cell
also
sought
viru
compar
virusbas
target
rel
greater
number
host
cellbas
target
identifi
includ
receptor
hiv
chemokin
receptor
coreceptor
hiv
carbohydratebind
antigen
cba
tuftsin
hladr
dcsign
howev
recent
studi
indic
promis
target
includ
hladr
dcsign
addit
infect
cellfre
virion
import
cellcel
spread
across
connect
membran
bridg
close
cellcel
contact
refer
virolog
synaps
vs
propag
increasingli
recogn
predomin
mechan
propag
tcell
assembl
tcell
vs
requir
engag
env
surfac
subunit
express
effector
cell
cellular
receptor
target
cell
recruit
receptor
protein
conjug
interfac
cytoskeletondepend
process
target
effector
cell
specif
vs
character
cluster
leukocyt
functionassoci
antigen
also
known
l
effectortarget
cell
interfac
lymphocyt
function
associ
antigen
belong
integrin
famili
adhes
molecul
hypothes
contribut
format
stabl
adhes
junction
effector
tcell
target
tcell
major
cognat
ligand
cell
furthermor
integrin
implic
cellcel
transmiss
dendrit
cell
dc
cell
via
dcsign
dcspecif
intercellular
adhes
molecul
grab
nonintegrin
probabl
role
set
maintain
robust
dctcell
contact
sinc
key
molecul
involv
transmiss
hiv
format
vs
tcell
dctcell
interact
recent
studi
target
potenti
antihiv
target
present
lymphocyt
b
lymphocyt
neutrophil
macrophag
express
high
hiv
infect
addit
also
recogn
hiv
envelop
glycoprotein
induc
high
level
express
immunoliposom
modifi
antibodi
target
integrin
receptor
develop
deliv
sirna
gene
evalu
efficaci
vitro
vivo
antibodi
link
liposom
abl
deliv
sirna
success
infect
cell
cyclic
peptid
cibr
cibl
cibc
deriv
abl
bind
intern
cell
express
idomain
thu
use
target
hiv
infect
cell
monoclon
antibodi
also
demonstr
exhibit
high
affin
cell
express
observ
bind
occur
present
lymphocyt
activ
hiv
infect
antibodi
bind
occur
inact
cell
thu
display
high
degre
select
toward
hiv
infect
cell
emerg
paradigm
use
monoclon
antibodi
direct
abil
inhibit
viral
replic
recent
studi
focus
understand
mechan
viral
replic
inhibit
found
bind
antibodi
free
viru
influenc
replic
effici
howev
bind
antibodi
present
hiv
infect
cell
result
product
solubl
factor
interf
viral
replic
henc
use
could
doubli
benefici
ensur
specif
target
hiv
infect
cell
well
inhibit
viral
inhibit
facet
howev
need
explor
indepth
addit
experi
vivo
fig
repres
concept
target
use
modifi
drug
load
nanoparticl
though
literatur
report
studi
target
nanoparticl
studi
promis
sure
open
avenu
detail
studi
target
antihiv
target
human
leukocyt
antigen
hla
receptor
belong
major
histocompat
class
mhc
protein
involv
present
antigen
lymphocyt
lead
activ
immun
respons
among
variou
mhc
class
ii
type
hladr
hladq
hladp
heterodimer
cell
surfac
receptor
found
macrophag
dendrit
cell
b
cell
present
antigen
helper
cell
due
local
surfac
cell
serv
hiv
reservoir
abil
attract
helper
cell
hla
cell
surfac
receptor
attract
target
moieti
hiv
infect
cell
interestingli
hladr
molecul
express
increas
hiv
infect
along
transmembran
receptor
interleukin
recent
antihladr
molecul
use
target
hladr
express
hiv
infect
cell
immunoliposom
load
proteas
inhibitor
indinavir
surfac
modifi
antihladr
found
effect
bind
hiv
infect
cell
deliv
antiretrovir
drug
lead
signific
reduct
viral
load
anoth
studi
biodistribut
antihladr
conjug
immunoliposom
evalu
use
mice
model
found
immunoliposom
concentr
secondari
lymphoid
organ
like
spleen
lymph
node
main
reservoir
hiv
virion
uniqu
advantag
acquir
use
antihladr
modifi
liposom
abl
bind
hiv
infect
cell
also
free
hiv
virion
found
entrap
follicular
dendrit
cell
network
also
report
viral
reservoir
monocyt
macrophag
dendrit
cell
difficult
target
due
dormant
natur
virus
easili
target
use
antihladr
due
high
level
hladr
express
cell
therefor
reduc
undesir
toxic
antiretrovir
drug
normal
cell
also
observ
liposom
antihladr
preferenti
accumul
lymph
node
rich
hiv
infect
cell
immunoliposom
conjug
antihladr
load
amphotericin
b
inhibitor
hiv
replic
also
report
target
hiv
infect
cell
reduc
viral
load
immunoliposom
system
encapsul
sirna
rev
tat
gene
hiv
involv
replic
process
success
deliv
target
cell
conjug
antibodi
hlab
hlac
belong
mhc
class
molecul
evid
scan
literatur
antihla
antibodi
conjug
liposom
alon
report
nanocarri
modifi
hladr
yet
explor
one
major
challeng
hla
target
lie
design
antibodi
high
specif
due
presenc
larg
number
serotyp
hla
furthermor
hladr
cell
show
increas
suscept
hiv
infect
also
produc
support
higher
viral
replic
level
compar
cell
hiv
peptid
show
high
affin
hladr
moieti
studi
also
demonstr
high
affin
certain
hivderiv
peptid
hladr
cell
surfac
studi
indic
hladr
incorpor
viral
envelop
bud
stage
hiv
cycl
facilit
infect
uninfect
cell
use
receptor
receptor
taken
togeth
studi
indic
target
hladr
deliv
antiretrovir
drug
possibl
site
hiv
infect
may
also
attenu
hladrmedi
spread
viral
infect
bodi
ctype
lectin
dcsign
dc
specif
nonintegrin
identifi
cell
surfac
receptor
immatur
dc
bind
hiv
mediat
transfer
viru
permiss
cell
contact
dcsign
thu
first
event
pathogen
cascad
therefor
primari
target
point
therapi
aim
hiv
infect
prevent
dcsign
bind
hiv
result
intern
viru
nonendolysosom
compart
compart
intern
viru
move
rapidli
synaps
form
infect
dc
cell
transmiss
virion
mainli
due
interact
follow
tetram
format
result
higher
affin
dcsign
residu
thu
result
fusion
membran
captur
transfer
hiv
virion
dendrit
cell
posit
cell
silenc
dcsign
express
hiv
infect
cell
shown
reduc
viral
load
thu
confirm
potenti
dcsign
function
potenti
target
molecul
bind
dcsign
import
target
hiv
infect
cell
includ
polyman
bind
specif
dcsign
express
hiv
infect
cell
thu
dcsign
could
critic
target
combat
earli
hiv
infect
cell
surfac
glycoprotein
glycoprotein
cluster
differenti
belong
immunoglobulin
famili
express
surfac
sever
immun
cell
includ
lymphocyt
monocyt
macrophag
dendrit
cell
elicit
immun
respons
interact
antigen
present
major
histocompat
complex
mhc
molecul
antigen
present
cell
hiv
hijack
primari
receptor
invad
target
cell
therefor
target
moieti
attract
stratagem
select
deliv
antihiv
drug
target
cell
target
cell
achiev
antibodi
design
bind
specif
four
domain
present
liposom
carrier
conjug
antibodi
domain
develop
specif
bound
hiv
infect
cell
similarli
conjug
liposom
employ
deliveri
sirna
silenc
rev
gene
implic
regul
express
virion
protein
signific
amount
viral
inhibit
observ
due
effect
target
cell
recent
work
lipid
nanoparticl
conjug
two
peptid
sequenc
deriv
bind
domain
design
use
target
deliveri
proteas
inhibitor
indinavir
hiv
infect
cell
high
specif
one
major
challeng
target
cell
possibl
interfer
normal
function
express
cell
normal
condit
use
lymphocyt
bind
mhc
major
histocompat
complex
class
ii
protein
antigen
recognit
bind
domain
involv
interact
mhc
class
ii
overlap
bind
domain
involv
interact
hiv
differ
higher
contact
area
stronger
affin
therefor
design
peptidomimet
greater
affin
explor
may
also
serv
competit
inhibitor
bind
use
peptid
target
drugload
nanoparticl
howev
explor
thu
far
hivinfect
cell
target
also
achiev
use
engin
cytotox
lymphocyt
ctl
express
chimera
receptor
employ
extracellular
portion
target
moieti
specif
bind
engin
cell
receptor
cell
result
activ
signal
pathway
ctl
caus
lysi
hiv
infect
cell
novel
concept
experi
late
develop
viraceut
involv
engin
virus
rhabdovirida
famili
devoid
envelop
protein
express
coreceptor
enabl
select
seek
bound
cell
destroy
howev
success
demonstr
clinic
setup
yet
realiz
departur
convent
concept
target
cell
deliveri
antiretrovir
inhibit
viral
entri
recent
report
employ
conjug
gold
nanoparticl
visual
lymph
node
xray
comput
tomographi
applic
employ
futur
develop
theranost
system
enabl
simultan
visual
infect
cell
treatment
use
coadminist
therapeut
agent
viral
entri
cell
facilit
presenc
coreceptor
also
employ
target
hiv
infect
cell
cc
chemokin
receptor
type
belong
beta
chemokin
receptor
famili
act
receptor
mani
chemokin
macrophag
inflammatori
protein
mip
express
cell
macrophag
microgli
cell
dendrit
cell
also
import
coreceptor
recruit
hiv
viru
gain
entri
host
cell
believ
involv
later
stage
viral
infect
involv
entri
viru
earli
phase
hiv
infect
result
remain
among
extens
investig
chemokin
receptor
target
control
spread
hiv
infect
liposom
system
coval
link
encapsul
model
drug
ethylen
diaminetetraacet
acid
edta
target
hiv
infect
cell
express
along
solubl
possess
affin
toward
hiv
liposom
bind
infect
cell
caus
select
death
presenc
solubl
monoclon
antibodi
develop
also
employ
home
hiv
infect
cell
monoclon
antibodi
bind
multipl
extracellular
domain
therefor
select
deliv
antiretrovir
drug
effici
hiv
infect
cell
conjug
nanoparticl
natur
ligand
chemokin
cc
ligand
also
refer
rant
regul
activ
normal
cell
express
secret
also
use
deliv
therapeut
moieti
hiv
infect
cell
synthet
peptid
deriv
sequenc
extracellular
loop
involv
interact
viral
protein
also
employ
target
hiv
infect
cell
synthet
peptid
demonstr
bind
present
surfac
viru
infect
cell
classic
exampl
categori
peptid
peptid
refer
resembl
extracellular
loop
high
affin
therefor
use
target
hiv
infect
cell
novel
approach
peptid
nucleic
acid
pna
specif
toward
gene
encapsul
biodegrad
nanoparticl
plga
poli
llactidecoglycolid
deliv
hiv
infect
cell
pna
associ
gene
hoogsteen
bond
result
suppress
gene
express
lead
condit
akin
found
cell
carri
mutat
cell
turn
hiv
resist
due
absenc
express
cell
surfac
therebi
prevent
entri
hiv
chemokin
receptor
type
also
known
fusin
transmembran
protein
belong
g
protein
coupl
receptor
famili
ubiquit
express
sever
cell
type
includ
lymphocyt
endotheli
cell
tumor
cell
natur
ligand
receptor
stromal
deriv
serv
chemoattract
lymphocyt
ubiquitin
implic
mitig
proinflammatori
molecul
strain
design
ttropic
gain
entri
host
cell
bind
interact
believ
primari
bind
facilit
conform
chang
viral
protein
bind
also
found
sever
strain
abl
gain
entri
even
cell
receptor
suggest
virus
possess
envelop
protein
bind
specif
chemokin
receptor
small
basic
bicyclam
molecul
synthes
exhibit
high
affin
bind
molecul
found
use
target
cancer
therapi
wound
heal
apart
potenti
antihiv
properti
howev
therapeut
use
hiv
infect
limit
viral
load
reduct
postadministr
drug
signific
case
viru
abl
gain
entri
chemokin
receptor
antibodi
peptid
sequenc
direct
use
target
hiv
infect
cell
peptid
sequenc
deriv
viral
macrophag
protein
vmipii
design
investig
target
affin
toward
found
exhibit
moder
affin
display
high
affin
toward
henc
explor
target
posit
cell
recent
studi
peptid
deriv
amino
acid
sequenc
nterminu
viral
macrophag
inflammatori
protein
vmipii
encapsul
nanoliposom
carrier
liposom
system
found
inhibit
induc
chemotact
activ
peripher
blood
mononuclear
cell
competit
bind
antibodi
also
use
target
hiv
infect
cell
possibl
recognit
specif
sequenc
extracellular
loop
current
human
antibodi
design
preclin
trial
evalu
target
efficaci
stromal
cell
deriv
secret
bone
marrow
stromal
cell
also
use
target
hiv
infect
cell
two
type
sdf
name
investig
due
high
affin
easi
bind
receptor
therebi
serv
promis
target
moieti
toward
h
cell
infect
hiv
convers
also
link
nanocarri
target
hiv
infect
cell
due
affin
viral
present
surfac
hiv
infect
cell
transmembran
protein
deriv
also
demonstr
bind
cell
use
target
hiv
infect
cell
synthet
pentapeptid
employ
inhibitori
peptid
hiv
infect
found
exhibit
superior
bind
affin
toward
coreceptor
monoclon
antibodi
select
bind
two
synthet
antagonist
polypeptid
demonstr
differ
cancer
cell
type
henc
promis
moieti
target
hiv
infect
cell
howev
peptid
evalu
hiv
infect
cell
yet
recent
emerg
nanobodi
singl
domain
antibodi
contain
singl
chain
variabl
domain
bind
antigen
result
develop
display
high
affin
bind
compar
nanobodi
bind
loop
current
phase
ii
clinic
trial
potenti
target
ligand
toward
hiv
infect
cell
evalu
viral
envelop
contain
mani
glycan
residu
aid
specif
bind
host
cell
also
serv
evad
immun
recognit
mask
immun
epitop
mannos
residu
import
bind
moieti
surfac
hiv
glycoprotein
target
sugar
moieti
effect
strategi
specif
home
onto
hiv
infect
cell
numer
glycan
residu
expos
surfac
hiv
infect
cell
concept
led
emerg
carbohydr
bind
agent
cba
broadli
classifi
either
lectin
belong
protein
famili
nonpeptid
molecul
specif
toward
particular
type
sugar
moieti
apart
impart
abil
select
bind
viral
envelop
therebi
block
abil
interact
host
cell
surfac
receptor
repeat
use
cba
also
induc
viru
delet
glycan
residu
therebi
lead
unmask
hidden
immun
epitop
result
immun
activ
glycan
residu
also
involv
fold
protein
nativ
conform
delet
glycan
residu
viru
respons
treatment
cba
therefor
indirectli
hamper
function
glycan
protein
fold
therebi
reduc
virul
viru
host
peptid
cba
name
lectin
identifi
differ
plant
microbi
mammalian
sourc
apart
origin
lectin
differ
size
specif
toward
sugar
residu
impact
bind
affin
well
viral
inhibit
activ
gener
identifi
lectin
display
specif
toward
oligom
exhibit
better
viral
bind
inhibit
compar
lectin
exhibit
specif
carbohydr
moieti
except
gener
lectin
isol
sting
nettl
urtica
dioica
refer
uda
u
dioica
agglutinin
display
specif
toward
nacetyl
glucosamin
moieti
also
display
signific
affin
toward
hiv
glycan
envelop
lectin
cyanovirinn
cvn
extract
cyanobacterium
nostoc
ellipsosporum
found
bind
residu
high
affin
similarli
scyctovirin
svn
lectin
extract
cyanobacterium
scytonema
varium
exhibit
select
residu
found
bind
hiv
glycoprotein
present
surfac
hiv
infect
cell
lectin
sourc
eukaryot
origin
gsa
gerardia
savaglia
agglutinin
sea
coral
g
savaglia
display
calcium
depend
bind
dmannos
residu
glycoprotein
envelop
result
complet
viral
inhibit
vitro
condit
lectin
actinohivin
isol
actinomycet
longisporum
albida
also
identifi
import
target
moieti
bind
mannos
residu
present
lower
concentr
affin
greater
antibodi
therebi
prevent
interact
viral
glycoprotein
chemokin
receptor
griffithsin
lectin
isol
red
alga
griffithsia
speci
identifi
possess
specif
bind
mannos
glucos
fucos
nacetyl
glucosamin
moieti
thu
confer
broad
spectrum
activ
lectin
toward
differ
viral
strain
griffithsin
found
effect
interf
interact
viral
glycoprotein
well
also
shown
promis
inhibit
sar
coronaviru
bind
outer
glycoprotein
coat
sar
sever
compromis
acut
respiratori
distress
syndrom
viru
lectin
bca
boodlea
coacta
agglutinin
extract
green
alga
b
coacta
show
structur
similar
galanthu
nivali
agglutinin
gna
isol
snowdrop
plant
act
potent
target
moieti
hiv
infect
cell
shown
bind
mainli
type
nglycan
present
hiv
envelop
glycoprotein
high
affin
make
promis
target
agent
hiv
infect
cell
bind
affin
bca
found
increas
increas
number
mannos
residu
cluster
lectin
molecul
identifi
possess
specif
affin
toward
mannos
residu
hiv
glycoprotein
cvl
chaetopteru
variapedatu
lectin
isol
annelid
worm
c
variapedatu
npa
narcissu
pseudonarcissu
agglutinin
daffodil
plant
n
pseudonarcissu
scl
scilla
campanulata
lectin
bluebel
plant
campanulata
cona
concanavalin
jack
bean
canavalia
ensiformi
jacalin
jack
fruit
artocarpu
integrifolia
mbl
mannos
bind
lectin
found
serum
mammalian
system
display
calciumdepend
bind
mannos
residu
dcsign
dendrit
cellspecif
intercellular
adhes
moleculegrab
nonintegrin
express
dendrit
cell
mammalian
system
specif
toward
mannotrios
residu
etc
uniqu
lectin
refer
mermaid
ctype
lectin
express
surfac
marin
nematod
laxu
oneistu
identifi
possess
structur
similar
dcsign
lectin
bind
high
affin
found
inhibit
bind
viru
dendrit
cell
well
inhibit
transmiss
viru
dendrit
cell
lymphocyt
yet
anoth
class
cation
cysteinerich
peptid
express
leukocyt
defensin
possess
antivir
properti
differ
isoform
defensin
name
identifi
defensin
promot
chemotaxi
lymphocyt
also
display
abil
inhibit
viral
entri
replic
antivir
activ
defensin
mainli
attribut
abil
interfer
pkc
protein
kinas
c
signal
hiv
infect
cell
well
enhanc
cc
chemokin
level
cell
lead
competit
inhibit
viral
bind
host
cell
defensin
also
known
retrocyclin
display
similar
lectin
bind
specif
glycan
residu
hiv
envelop
henc
could
serv
glycantarget
moieti
recent
attempt
encapsul
defensin
peptid
along
residu
biodegrad
poli
llactidecoglycolid
microparticl
report
presenc
defensin
result
elev
immunogen
respons
hiv
henc
propos
strategi
could
effect
vaccin
hiv
infect
earli
work
glycan
target
employ
mannos
target
moieti
toward
mannos
receptor
present
hiv
infect
cell
like
macrophag
dendrit
cell
astrocyt
result
increas
uptak
mannoselink
drugload
nanoparticl
receptormedi
endocytosi
lead
decreas
viral
load
antibodi
glycan
residu
hiv
also
use
target
moieti
monoclon
antibodi
oligosaccharid
glycoprotein
report
bind
expos
glycan
residu
surfac
hiv
infect
cell
high
affin
one
common
monoclon
antibodi
employ
target
glycan
residu
bind
specif
hiv
termin
mannos
oligom
howev
mutat
region
result
delet
residu
might
render
antibodi
ineffect
issu
commonli
encount
use
cba
capabl
bind
multipl
residu
glycoprotein
sequenc
result
numer
delet
mutat
effect
viru
achiev
resist
cba
high
genet
barrier
achiev
cba
make
attract
therapeut
moieti
also
use
achiev
target
specif
among
nonpeptid
cba
antibiot
pradimicin
prma
nanomicin
bnma
actinomycet
speci
found
exhibit
calcium
depend
bind
termin
dmannos
viral
glycoprotein
form
ternari
complex
concert
effort
develop
low
molecular
weight
nonpeptid
molecul
carbohydratespecif
bind
underway
mani
research
laboratori
liposom
carrier
contain
ctype
lectin
high
bind
specif
toward
dcsign
develop
found
exhibit
excel
targetspecif
deliveri
cargo
fluoresc
calcein
suggest
carrier
may
use
context
sitedirect
deliveri
therapeut
agent
use
glycan
residu
immunostimulatori
purpos
also
attempt
strategi
reduc
viral
infect
order
achiev
highli
effect
multival
display
carbohydr
moieti
stimul
immun
system
novel
structur
glycoclust
glycodendrim
also
report
literatur
concept
use
cba
part
antihiv
arsen
howev
hamper
mani
factor
high
expens
involv
isol
purif
cba
storag
stabil
issu
mitogen
natur
lectin
poor
bioavail
inabl
distinguish
pathogen
glycan
target
nativ
host
glycan
residu
remain
address
could
use
clinic
setup
tuftsin
tetrapeptid
deriv
immunoglobin
igg
spleen
consist
amino
acid
sequenc
thrlysproarg
sinc
discoveri
tuftsin
found
applic
immunotherapi
due
abil
bind
activ
macrophag
dendrit
cell
bind
tuftsin
tuftsin
receptor
express
surfac
cell
immun
system
activ
chemotaxi
phagocytosi
cell
also
serv
viral
reservoir
hiv
infect
employ
tuftsin
target
infect
cell
explor
potenti
treatment
strategi
aid
drugtuftsin
conjug
develop
coval
link
tuftsin
revers
transcriptas
inhibitor
azt
conjug
effect
use
target
macrophag
hoard
hiv
virion
signific
decreas
viral
load
compar
free
drug
achiev
thu
illustr
specif
target
potenti
tuftsin
tuftsin
moieti
also
stimul
releas
cytokin
interleukin
macrophag
therebi
increas
immun
respons
propylen
imin
ppi
dendrim
load
revers
transcriptas
inhibitor
efavirenz
conjug
tuftsin
evalu
antivir
efficaci
vitro
use
macrophag
tuftsinconjug
dendrim
significantli
decreas
viral
load
compar
unconjug
ppi
dendrim
suggest
tuftsin
conjug
enhanc
uptak
infect
cell
tuftsin
conjug
liposom
also
extens
investig
treatment
tuberculosi
malaria
leishmaniasi
fungal
infect
howev
apart
report
tuftsin
conjug
dendrim
system
studi
involv
tuftsinconjug
nanocarri
remain
larg
unexplor
context
hiv
therapi
transferrin
import
ironbind
glycoprotein
present
blood
primarili
involv
mainten
iron
level
biolog
system
affin
iron
transferrin
extrem
high
physiolog
ph
decreas
decreas
ph
transferrin
receptor
abundantli
present
liver
brain
physiolog
condit
brain
import
sanctuari
hiv
essenti
deliv
antiretrovir
drug
across
bloodbrain
barrier
transferrin
receptor
express
high
brain
possibl
deliv
therapeut
agent
brain
transferrinconjug
nanocarri
intern
use
receptormedi
endocytosi
transferrinconjug
plga
nanoparticl
encapsul
revers
transcriptas
inhibitor
nevirapin
success
transport
across
bloodbrain
barrier
human
brain
microvascular
endotheli
cell
similar
strategi
report
enabl
deliveri
hiv
model
antigen
epitheli
barrier
mucos
layer
transferrinconjug
system
abl
elicit
higher
immun
respons
evid
high
titer
obtain
antibodi
igg
iga
genit
tract
femal
mice
compar
unconjug
system
specif
antibodi
transferrin
receptor
name
bind
cell
express
transferrin
receptor
conjug
streptavidin
moieti
deliv
antisens
oligonucleotid
rev
gene
hiv
modifi
coval
biotin
molecul
biotinyl
protect
oligonucleotid
exonucleas
degrad
enabl
bind
transferrin
conjug
streptavidin
system
found
increas
inactiv
rev
mrna
cerebr
region
compar
free
oligonucleotid
highlight
abil
transferrin
conjug
system
cross
bloodbrain
barrier
albumin
nanoparticl
encapsul
nucleosid
revers
transcriptas
inhibitor
azidothymidin
azt
surfac
modifi
transferrin
found
cross
bloodbrain
barrier
effici
decreas
viral
load
biodistribut
studi
nanoparticul
system
albino
rat
reveal
select
enhanc
uptak
nanoparticl
brain
illustr
target
efficaci
transferrin
investig
relat
iron
level
hiv
infect
reveal
hiv
infect
lead
increas
oxid
stress
cell
also
caus
releas
intracellular
iron
store
result
iron
overload
observ
transferrin
receptor
express
infect
cell
reduc
henc
advanc
stage
infect
remain
seen
transferrin
receptor
could
still
effect
target
departur
convent
carrier
use
modifi
transferrin
drug
carrier
report
proof
principl
work
author
insert
peptid
sequenc
transferrin
recogn
hiv
proteas
enzym
system
success
demonstr
enter
hiv
infect
cell
lyse
hiv
proteas
enzym
explor
drug
deliveri
hiv
infect
cell
quantum
rod
compris
cadmium
selenid
core
grade
cadmium
sulfidezinc
sulfid
shell
conjug
transferrin
complex
saquinavir
treatment
neuroaid
complex
found
extrem
effect
transport
saquinavir
across
bloodbrain
barrier
aptam
challeng
conjug
antibodi
carrier
primarili
due
chang
conform
induc
chemic
treatment
step
result
loss
target
specif
necessit
develop
novel
small
molecul
ligand
retain
target
specif
antibodi
greater
structur
stabil
aptam
small
molecul
singl
strand
oligonucleotid
dna
rna
peptid
excel
target
specif
aptam
develop
use
selex
systemat
evolut
ligand
exponenti
enrich
seri
sequenti
step
involv
bind
separ
purif
amplif
aptam
also
possess
abil
hybrid
watsoncrick
pair
henc
use
form
chimer
structur
molecul
sirna
ribozym
use
deliveri
desir
locat
chimer
aptamersirna
system
exhibit
specif
toward
report
enter
hiv
infect
cell
endocytosi
aptamersirna
chimera
cleav
dicer
insid
cell
lead
releas
sirna
bind
mrna
hiv
tat
rev
gene
inhibit
hiv
life
cycl
aptam
bind
specif
hiv
infect
cell
develop
aptam
bind
infect
cell
report
could
employ
target
hiv
infect
cell
sever
aptam
specif
toward
hiv
revers
transcriptas
integras
nucleoprotein
gag
protein
tat
protein
rev
protein
transactiv
respons
element
tar
report
novel
aptam
grich
repeat
spontan
form
gquadruplex
presenc
dival
ion
hoogsteen
pair
develop
hiv
integras
termin
modif
quadruplex
aptam
display
extraordinari
stabil
bind
specif
target
aptam
immens
potenti
field
target
deliveri
antiretrovir
remain
explor
indepth
lowdens
lipoprotein
ldl
lowdens
lipoprotein
ldl
type
lipoprotein
involv
transport
lipid
cell
ldl
abil
attract
macrophag
henc
explor
possibl
target
moieti
hiv
infect
macrophag
ldl
conjug
azt
azidothymidin
demonstr
intern
macrophag
ldl
receptormedi
endocytosi
deliv
drug
similar
studi
carri
use
ldl
conjug
fluorothymidin
bind
macrophag
infect
hiv
deliv
drug
effect
caus
decreas
viral
load
compar
free
drug
anoth
studi
employ
acetyl
ldl
load
azt
sitespecif
deliveri
macrophag
uptak
acetyl
ldl
modifi
carrier
achiev
scaveng
receptor
result
decreas
viral
load
howev
observ
hiv
infect
result
decreas
express
ldl
receptor
henc
target
receptor
advanc
stage
diseas
might
effect
strategi
passiv
target
involv
chemic
modif
carrier
intern
desir
locat
mainli
driven
specif
properti
target
cell
concept
passiv
target
well
exploit
cancer
therapeut
util
enhanc
permeat
retent
epr
properti
cancer
cell
case
hiv
infect
dendrit
cell
macrophag
high
amount
virion
found
transfer
h
cell
virolog
synaps
macrophag
dendrit
cell
observ
highli
activ
hiv
infect
exhibit
higher
phagocyt
properti
uninfect
cell
enhanc
phagocyt
activ
macrophag
har
entrap
antiretrovir
load
carrier
cell
infect
hiv
strategi
passiv
target
success
demonstr
use
indinavir
encapsul
liposom
nanoparticl
prepar
use
synthet
phospholipid
phosphatidyl
cholin
phosphatidyl
ethanolamin
stabil
agent
nanoparticl
exhibit
good
uptak
hiv
infect
macrophag
reduc
viral
load
significantli
compar
solubl
indinavir
differ
encapsul
free
form
drug
mainli
attribut
phagocytosi
nanoparticl
macrophag
anoth
approach
selfassembl
dual
drug
conjug
azt
zidovudin
didanosin
ddi
separ
adeoxycholyl
spacer
synthes
zidovudinephosphoryldeoxycholyl
didanosin
zpdd
conjug
easili
intern
phagocyt
macrophag
result
destruct
virion
schemat
represent
nanoparticl
intern
infect
cell
passiv
target
shown
fig
target
moieti
hiv
posit
cell
explor
thiamin
glutathion
albumin
moieti
easili
pass
bloodbrain
barrier
effici
deliv
drug
conjug
nanocarri
yet
anoth
strategi
still
proof
principl
stage
use
triblock
copolym
poli
ethylen
oxid
poli
propylen
oxid
micel
carrier
disabl
efflux
pump
hiv
infect
cell
trigger
infect
achiev
multidrug
resist
pluron
polym
unim
alter
mitochondri
membran
fluiditi
therebi
disrupt
electron
transport
chain
impair
atp
product
lead
shutdown
efflux
pump
strategi
may
enabl
sensit
hiv
infect
cell
antiretrovir
therebi
enhanc
therapeut
effici
investig
use
knockdown
experi
next
gener
sequenc
unravel
complex
interact
hiv
human
protein
help
identif
potenti
target
could
explor
futur
therapeut
applic
recent
report
novel
viral
accessori
factor
vif
identifi
recruit
human
transcript
factor
core
bind
factor
subunit
beta
use
ubiquitinligas
complex
degrad
restrict
factor
retrovir
complementari
dna
deaminas
human
system
inactiv
viral
replic
target
vif
might
offer
better
chanc
curb
viral
replic
anoth
novel
target
could
glycoprotein
found
inhibit
replic
tropic
tropic
hiv
probabl
modif
cytoskeleton
dynam
could
also
explor
indepth
therapeut
target
viral
infect
novel
approach
melittin
activ
compon
bee
toxin
encapsul
liposom
nanoparticl
evalu
antihiv
activ
melittin
activ
phospholipas
enzym
destroy
cell
disrupt
lipid
coat
cytolyt
agent
found
select
intern
greater
extent
hiv
infect
cell
destroy
viral
lipid
coat
though
free
melittin
also
found
destroy
viru
cytotox
toward
normal
cell
significantli
high
compar
nanoparticl
counterpart
display
select
toxic
viru
system
display
toxic
toward
tropic
virus
attack
lipid
coat
probabl
viru
develop
resist
toward
molecul
remot
system
need
evalu
valid
clinic
signific
rna
silenc
emerg
import
strategi
combat
aid
infect
mani
new
viral
target
identifi
silenc
use
rnai
technolog
target
target
rnai
technolog
includ
structur
regulatori
accessori
gene
gag
pol
env
rev
tat
tar
vif
nef
vpx
vpr
etc
attempt
silenc
factor
trigger
host
cell
result
hiv
infect
golgi
transport
protein
karyopherin
mediat
complex
also
made
control
hiv
infect
howev
success
rnai
depend
complex
suitabl
nanocarri
well
identif
target
moieti
select
deliv
infect
cell
also
new
emerg
paradigm
may
necessari
silenc
one
gene
target
simultan
ensur
total
disrupt
hiv
virion
studi
yet
explor
indepth
therebi
leav
field
wide
open
research
tabl
list
numer
target
nanocarri
explor
hiv
therapi
indic
tremend
scope
investig
employ
combin
therapeut
agent
nanocarri
target
agent
continu
vital
need
newer
agent
confront
emerg
drug
resist
variou
advers
effect
longterm
use
arv
therapi
also
halflif
sever
arv
drug
short
requir
frequent
administr
dose
turn
lead
poor
patient
complianc
therefor
usag
novel
drug
deliveri
system
logic
approach
overcom
problem
effect
treat
hiv
infect
among
recent
therapeut
approach
fig
schemat
represent
passiv
target
strategi
employ
nanoparticl
major
thrust
area
develop
effect
drug
deliveri
system
exist
drug
test
proven
effect
reduc
viral
load
review
need
novel
drug
deliveri
advantag
recent
develop
identif
viral
host
surfac
molecul
marker
target
drug
deliveri
antiretrovir
drug
discuss
studi
open
new
avenu
indepth
studi
effect
use
target
strategi
hiv
therapi
comprehens
approach
could
ultim
prove
effect
reduc
viral
load
also
erad
viru
reservoir
envisag
futur
direct
field
involv
multiprong
strategi
target
hiv
variou
stage
infect
includ
transmiss
virion
dendrit
cell
macrophag
cell
potenti
target
hladr
dcsign
furthermor
celltocel
transmiss
hiv
cell
virolog
synaps
also
critic
stage
viral
transmiss
bodi
case
celltocel
transmiss
like
emerg
potenti
target
target
antihiv
therapi
anoth
key
area
involv
counter
challeng
target
latent
hiv
multipl
reservoir
regard
strategi
combin
releas
hiv
virion
latent
infect
cell
activ
protein
kinas
pathway
along
antihiv
drug
deliveri
hold
tremend
potenti
summari
recent
scientif
advanc
develop
target
drug
deliveri
antihiv
drug
hold
great
promis
develop
improv
treatment
strategi
certainli
pave
way
toward
global
erad
hivaid
chimer
aptam
rnai
vitro
